China-based MobiDrop (Zhejiang) Co., Ltd has reportedly raised close to RMB 100 million (USD 14.8 million) in a Series A+ financing round led by LYFE Capital. Existing investor Source Code Capital and a government-led fund also participated.
Funding Use
Proceeds will support the expansion of MobiDrop’s single-cell product pipeline, research and development (R&D), and promotion of MobiMicrobe, a high-throughput microbial single-cell genomics platform. The company will also allocate funds to R&D, manufacturing, commercialization, and market development for other products.
Company Background
Founded in 2018 at Harvard University, MobiDrop focuses on advancing scientific research and precision medicine through innovative microfluidics and single-cell sequencing technologies. The company, which completed a RMB 150 million (USD 22.2 million) Series A financing in August 2022, offers single-cell sequencing and digital PCR product lines.-Fineline Info & Tech
